CRISPR/Cas-9 Technologies: A Call for a New Form of Tort

Authors

Kendall Lovell

Library of Congress Authority File

http://id.loc.gov/authorities/names/n79122466

Document Type

Comment

Abstract

Once relegated to the domains of science fiction, modern day scientists and researchers are poised on the precipice of making genome editing clinically available. Once introduced into a clinical setting the effects of an off-target mutation or germline edit will remain largely unknown until health issues arise later in life or in the following generation. The novelty of the injuries that will arise require a system that is able to balance the interests of physicians with single and multi-generational plaintiffs, while providing a realistic framework for courts to follow. This comment offers a brand-new context that accounts for these needs and sets expectations for how to handle these injuries in the right way, promulgating the goals of tort law.

Recommended Citation

Kendall Lovell, CRISPR/Cas-9 Technologies: A Call for a New Form of Tort, 19 San Diego Int'l L.J. 407 (2018)
Available at: https://digital.sandiego.edu/ilj/vol19/iss2/7